Merck Reports Discontinuation Of Phase 3 KeyVibe-008 Trial Based On Recommendation Of An Independent Data Monitoring Committee
Author: Benzinga Newsdesk | August 08, 2024 06:47am
At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria. Additionally, when compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs. A comprehensive analysis of this study is ongoing.
Posted In: MRK